Data from canine and porcine studies of Boston Scientific’s Watchman FLX Pro left-atrial appendage closure (LAAC) device suggest the device's new thromboresistant coating may further reduce the risk of device-related thrombus and reduce the patients' need to take anticoagulant drugs.
Watchman FLX Pro is the next-generation version of Boston Scientific’s Watchman FLX LAAC device intended to reduce the risk of...